do_not_disturb_altRecruitment Complete

Multiple sclerosis (MS)

Bayer Identifier:

21334

ClinicalTrials.gov Identifier:

NCT06053749

EudraCT Number:

Not Available

EU CT Number:

Not Available
An observational study to learn about the interferon-beta exposure of pregnant women during the second and third trimester in Finland and Sweden

Trial purpose

Observational data have suggested no increased risk of adverse pregnancy outcomes associated with exposure to interferon-beta (IFNB) before or during pregnancy. After the emergence of these data, the European Medicines Agency approved a label change for IFNB in September 2019, stating that use of IFNB during pregnancy may be considered, if clinically needed. However, limited data on pregnancies exposed in the 2nd and 3rd trimesters were observed.

INFORM is a secondary use of data drug utilisation study (DUS) to determine late pregnancy exposure (i.e. during the 2nd and 3rd trimester) to IFNB in Finland and Sweden, which will inform whether the number of exposed pregnancies is adequate to conduct a cohort study on adverse pregnancy outcomes, with a focus on late pregnancy exposure.

The number of pregnancies will be initially reported three years after the revised label implementation (September 2019) and will include data on pregnancies from 1996 in Finland and from 2005 in Sweden up through 31 December 2022. If the number of pregnancies is deemed adequate for conducting the cohort study on adverse pregnancy outcomes, this DUS will be finalised with the drug utilisation data accrued up through 31 December 2022. If the number of pregnancies until 31 December 2022 is deemed inadequate, this study may be continued and the primary and secondary objectives may be examined five years after the revised label implementation, including pregnancies until 31 December 2024.

Key Participants Requirements

Sex

Female

Age

12 - 64 Years
  • - Women with a diagnosis of MS disease, regardless of MS clinical type, recorded at least once during the full study period.
    - Women with at least one recorded pregnancy after the MS diagnosis (including pregnancies ending in live birth, stillbirth, spontaneous abortion, ectopic pregnancy, or elective termination)
  • - None.

Trial summary

Enrollment Goal
4
Trial Dates
March 2024 - March 2026
Phase
N/A
Could I Receive a placebo
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Not yet recruiting
Many locationsMany locations, Finland
Not yet recruiting
Many locationsMany locations, Sweden

Primary Outcome

  • The number of pregnancies of women with MS, not allowing exposure to other MS Disease Modifying Drugs (MSDMDs)
    Analysis groups: Pregnancies exposed to IFNB only group and Pregnancies unexposed to IFNB nor other MSDMDs group.
    date_rangeTime Frame:
    Data recorded between 01 January 1996 – 31 December 2022 in Finland, and 01 July 2005 – 31 December 2022 in Sweden.
  • The level of precision for the risk of pre-defined adverse pregnancy outcomes in late pregnancy that can be obtained with the available number of exposed and unexposed pregnancies
    Pre-defined adverse pregnancy outcomes: - Anomalies: Major congenital anomalies (MCA); All anomalies, including minor and major - Fatal outcomes: Spontaneous abortions, Elective terminations, Stillbirth and Neonatal mortality - Growth outcomes: Small for gestation age and Low birth weight - Other outcomes: Preterm birth Late pregnancy, i.e. the 2nd and 3rd trimester.
    date_rangeTime Frame:
    Data recorded between 01 January 1996 – 31 December 2022 in Finland, and 01 July 2005 – 31 December 2022 in Sweden.
  • The annual number of pregnancies of women with MS in the exposure groups
    Analysis in Pregnancies exposed to IFNB only group.
    date_rangeTime Frame:
    Data recorded between 2015-2019 and 2020-2022.

Secondary Outcome

  • The number of pregnancies of women with MS in Finland and Sweden in exposure groups allowing exposure to other MSDMDs
    Analysis groups: Pregnancies exposed to IFNB (regardless of other MSDMDs) group and Pregnancies unexposed to IFNB (regardless of other MSDMDs) group
    date_rangeTime Frame:
    Data recorded between 01 January 1996 – 31 December 2022 in Finland, and 01 July 2005 – 31 December 2022 in Sweden.
  • The annual number of women with MS in childbearing age, and with dispensed IFNB
    date_rangeTime Frame:
    Data recorded between 2015 to 2022 in Finland and Sweden

Trial design

INFORM - Interferon-Beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-Based Drug Utilisation Study in Finland and Sweden
Trial Type
Observational
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.